"According to the New York Times, when asked what the FDA should do about Avandia, 12 of the 33 members of the panel voted that Avandia should be withdrawn from the market, ten voted that its use should be restricted together with enhanced label warnings, seven voted just to enhance the label warnings, and three voted that nothing should be changed, with one member abstaining."